Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988817 · ClinicalTrials.gov registry record · Phase 1
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
A Phase 1 study, sponsored by Genmab.
- Completed
- Registry status
- Phase 1
- Development phase
- 306
- Enrollment target
NCT02988817 is a Phase 1 study that has completed, run by Genmab. The registered enrollment target is 306 participants.
The verdict
NCT02988817, a Phase 1 study, has completed, sponsored by Genmab.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 306 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
Interventions
- BIOLOGICAL Enapotamab vedotin (HuMax-AXL-ADC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2016-11-23 |
| Est. Completion | 2021-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02988817
The ClinicalTrials.gov registry entry for NCT02988817 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enapotamab vedotin (HuMax-AXL-ADC) is the first listed.
NCT02988817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02988817 about?
NCT02988817 is a clinical study titled "Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors". The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
What is the current status of trial NCT02988817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 306 participants. The study started on 2016-11-23. Estimated completion is 2021-11-12.
What interventions are being tested in trial NCT02988817?
The interventions under investigation include: Enapotamab vedotin (HuMax-AXL-ADC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02988817?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.